Teprotumumab improves outcomes in thyroid eye disease
Treatment with teprotumumab in patients with active thyroid eye disease confers beneficial effects on proptosis, Clinical Activity Score, diplopia and quality of life, without increasing the incidence of serious adverse events, according to the results of a phase III trial.
